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Surgical guidance with fluorescence has been demonstrated in individual clinical trials for decades,
but the scientific and commercial conditions exist today for a dramatic increase in clinical value. In the
past decade, increased use of indocyanine green based visualization of vascular flow, biliary function,
and tissue perfusion has spawned a robust growth in commercial systems that have near-infrared
emission imaging and video display capabilities. This recent history combined with major preclinical
innovations in fluorescent-labeled molecular probes, has the potential for a shift in surgical practice
toward resection guidance based upon molecular information in addition to conventional visual and
palpable cues. Most surgical subspecialties already have treatment management decisions partially
based upon the immunohistochemical phenotype of the cancer, as assessed from molecular pathology
of the biopsy tissue. This phenotyping can inform the surgical resection process by spatial mapping
of these features. Further integration of the diagnostic and therapeutic value of tumor metabolism
sensing molecules or immune binding agents directly into the surgical process can help this field
mature. Maximal value to the patient would come from identifying the spatial patterns of molecular
expression in vivo that are well known to exist. However, as each molecular agent is advanced
into trials, the performance of the imaging system can have a critical impact on the success. For
example, use of pre-existing commercial imaging systems are not well suited to image receptor
targeted fluorophores because of the lower concentrations expected, requiring orders of magnitude
more sensitivity. Additionally the imaging system needs the appropriate dynamic range and image
processing features to view molecular probes or therapeutics that may have nonspecific uptake or
pharmacokinetic issues which lead to limitations in contrast. Imaging systems need to be chosen
based upon objective performance criteria, and issues around calibration, validation, and interpreta-
tion need to be established before a clinical trial starts. Finally, as early phase trials become more
established, the costs associated with failures can be crippling to the field, and so judicious use of
phase 0 trials with microdose levels of agents is one viable paradigm to help the field advance, but
this places high sensitivity requirements on the imaging systems used. Molecular-guided surgery has
truly transformative potential, and several key challenges are outlined here with the goal of seeing
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efficient advancement with ideal choices. The focus of this vision 20/20 paper is on the technological
aspects that are needed to be paired with these agents. C 2016 Author(s). All article content, except
where otherwise noted, is licensed under a Creative Commons Attribution 3.0 Unported License.
[http://dx.doi.org/10.1118/1.4951732]
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1. INTRODUCTION—HISTORICAL
DEVELOPMENTS TO CURRENT STATUS
In the past decade, there has been rapid growth in clinical
use in fluorescence to guide surgical procedures, and recent
FDA 510(k) clearance of four new systems in the last
two years. This growth has been from the use surgical
imaging of indocyanine green (ICG) for tissue perfusion
and vascular function.1–4 Now it is possible to take advantage
of this fluorescence imaging approach through development
of targeted agents which could be advanced into clinical use
for truly molecular-guided surgery, where the fluorescence
signal is both a molecular diagnostic as well as part of the
intraoperative decision making process,5–10 or even used to
determine when to activate molecular based therapy.11–17 In
principle, imaging signals for as many pertinent information
streams as is feasible could be possible, but this currently
includes just blood flow and tissue perfusion. Ideally signals
such as metabolic proteins and ions could be imaged or
immunologic receptors and cytokines with appropriately
accurate molecular probes. This paradigm would be analogous
to the codiagnostic imaging promoted by nuclear medicine18
or providing the specificity of gene analysis,19 where a targeted
imaging agent reports on the metabolic or immunologic
functions that are the therapeutic biological target. The
biomarker can be either measurement of receptor activity
or reporting on molecules upstream/downstream from it, but
the key feature is that the imaging informs the potential
efficacy of the therapeutic choice. In the case of optical
imaging, the natural utility is to directly guide surgical
oncology decisions at the point of care,20 but there is also an
extension of this where the fluorescent agent is also packaged
as a therapeutic, either directly as a photodynamic agent or
indirectly as part of a nanoparticle delivery system. While this
new paradigm is emerging, it is inhibited by the costs of how
agents are developed and tested, and concerns lie around the
appropriate imaging guidance tools and advancing the right
molecules for testing.21–23 In any emerging field, it is possible
that inappropriate choices made early could encumber the
development to the point where the paradigm is viewed as
a failure, even if other combination approaches might have
been more successful. As such, this paper describes the key
issues of imaging technologies, molecule evaluation plans,
and choices of when to advance into human trials, and some
of the economics needed to develop a viable paradigm for
molecular-guided surgery.
Basic research and development in fluorescence imaging
has been ongoing for decades,24–31 with major contributions
to the concepts and even clinical trials happening as early
at the 1940s. Most of the basic technology work has been a
continual evolution from clinical reflectance imaging systems
in endoscopy, colonoscopy, and colposcopy, as illustrated in
Fig. 1, with individual feedback from each subspecialty into
the development of new systems and molecules. The steps
in imaging system evolution are discussed in Sec. 2 of this
paper. Key differences for molecular guidance are the needs
to make the signal specific to the molecules of interest and the
expected concentration and contrast ratio, and to present the
information in a manner which is customized to the medical
specialty. Specialty areas in surface imaging in the skin, oral
cavity, esophagus, colon, bladder and cervix have each seen
innovations in technology and contrast agents, which led to
clinical trials. Laparoscopic32–37 and endoscopic38–43 methods
also have a natural synergy with fluorescence imaging because
of the common workflow of viewing the procedure on a
display screen, and the ease of shifting to different excitation
light fields with little background room light interference.
Neurosurgery is one of the early adopters of high technological
influence, because of the need for microprecision specificity
and the fact that neurosurgeons are already used to high
technological guidance in their procedures.2,9,44–49 Urology
has led the way in robotic surgery,50–52 which has now adopted
fluorescence guidance with an optional camera as one feature
in the system.53–57 Now that more probes become established
and systems have been optimized for their detection, adoption
into higher risk procedures is occurring, especially where
there is significant added value to the procedure, such as in
complex vascular procedures or surgical margin detection.
Clinical imaging with ICG has caused a doubling in
the number of published papers in the last ten years, and
much higher growth in approved procedures.1,58–64 This
use has expanded from simple vascular tracer imaging
to tissue perfusion viability, kidney function, biliary tract
function, lymph node detection, as well as many others under
investigation. Some alternative fluorescent agents being tested
have been aminolevulinic acid to produce protoporphyrin IX
(ALA-PpIX) for photodynamic therapy of skin lesions, or
proflavins as oral antiseptic agents,65,66 both of which also
work as fluorescent contrast agents. ALA-PpIX is perhaps one
of the most successful examples of a metabolic probe, first
advanced as a clinical tool almost twenty five years ago.67
PpIX is produced in the heme synthesis cycle,68 which is
upregulated in many cancers and has been shown to be a robust
guide in neurosurgery9,69–71 and bladder cancer detection,72–75
with approvals for use in both diagnostic settings in several
European countries. There has been explosive growth in basic
and applied research in more complex proteins, biologicals,
vesicles, and nanoparticles which can be used as optical
tracers, however with most of these waiting for translation
into human trials, with uncertain evidence that this could be
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F. 1. The two essential components of hardware systems and molecular probes are illustrated feeding to the development process of molecular-guided surgery
(center). The technological innovations feed to the center, but these also feed to and from the individual surgical subspecialties, around the central core ideas.
The most well developed and readily adopted system features and molecular probes are at top, with R&D pushing innovations downward, yet adoption of both
generally comes from the most well developed systems and probes first (top of outer circle). Commercial adoption tends to be at the more conservative end of
this (top of figure), and in many cases is the opposite of research innovations (bottom of figure). Additionally interaction through the surgical subspecialties
generally comes from the manufacturer outward, without significant interspecialty cross-fertilization.
funded. The key issues around advancing these exogenous
molecular contrast agents into human use need study, as is
detailed in Sec. 3 of this paper.
The components needed for growth in this diverging field
are agents with true specificity to the disease, as shown by
maximized contrast to background, and the imaging system
used must be optimized for this expected use, with customized
display/guidance tools that easily facilitate use. Producers
try to differentiate their systems based upon customized
features that address the intended indication. Each of these is
discussed in this review. Figure 1 illustrates that as innovation
progresses, the drive to more specialized probes and to more
specific features of the systems can be independent of the
surgical specialties, yet can penetrate them as needs arise.
Interestingly there appears to be less interaction between the
surgical subspecialties in terms of procedures than there is
feedback to and from the technological and molecular probe
advances, and it is these latter areas that then relay advances
to other specialty areas. However one other critical part of
development is to ensure that clinical trials are funded with
an economic model which realizes how transformative this
type of imaging could become, but also how risk prone it
is at the early stage. This tricky issue is discussed in Sec. 4
of the paper, outlining one possible model using microdose
studies, to lower the economic risk such that commercial
investment might be enticed. While the upfront risks of this
new procedure are high, the commercial and human benefits
could be profound in surgical oncology. Yet this paradigm
uses very low concentration doses, and so it requires even
more stringent demands upon the sensitivity of the imaging
system used.
2. IMAGING SYSTEMS—PERFORMANCE,
DIFFERENTIATION, MAXIMIZING FEATURE
CONTRAST, AND DISPLAY
Optical systems to image fluorescence in surgery have
been in constant evolution, with a very wide range of
systems from microscopy to macroscopy being developed.
In terms of adoption in surgery though, there have been
relatively few successfully marketed systems to date, with
the Novadaq SPY being the most widely used [Fig. 2(a),
top], but with now several new systems emerging into this
space. These new systems present with a greater diversity
in capabilities, such as superior ergonomics, white light
suppression, and adaptive gain for higher sensitivity and
dynamic range. The spike in usage of ICG for perfusion
imaging of tissue has driven this growth in the market place,
with several of the competing systems shown in Fig. 2(a). One
example of a highly differentiated system is the Zeiss Pentero
neurosurgical station, Fig. 2(b), which has been customized
to allow imaging options with all of the major dyes used
in neurosurgery, including indocyanine green, fluorescein,
and now aminolevulinic acid induced protoporphyrin IX.76–78
Each has its approved use, and even the kinetics analysis
of flow can be done in the software tool. This system, with
all of these fluorescence options, illustrates how advanced
the field has become within the neurosurgery specialty. The
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F. 2. Emerging commercial fluorescence surgical systems are differentiating themselves from simple NIR fluorescence of ICG, with additional wavelength
bands, optimized background rejection, kinetics analysis, and integration into higher level functionality systems. Some of the leading and newly introduced
systems are shown in (a) with more differentiation being a commercial driving factor. In (b), the Zeiss Pentero is highlighted, which has capabilities for 3
fluorescence channel options and a kinetics analysis of blood flow, integrated into a standard neurosurgical system. (See color online version.)
use of ALA-PpIX is approved in Germany and has been
carried out in a growing number of clinical trials in the United
States.
Despite rapid growth in systems, the factors that make a
fluorescence system truly successful are not well established.
Performance goals and specifications are somewhat lacking,
since this is being driven by the needs of surgical specialties,
rather than a concerted technological drive, and without
consensus studies or top-down oversight. As a result, it is
unfortunately quite easy for systems to vary in sensitivity
by orders of magnitude because of the range of components
and uses that make the up the systems.79 Key factors are
many, and currently there are working groups in several
societies fostering needed discussion of these issues, and work
toward a wider understanding of the pertinent issues. There is
convergence happening in some community documents and
guidelines, and these may inform regulatory and standards in
the future. All current systems have a single highly specialized
use, being driven toward the singular application of ICG
perfusion and flow imaging. The technical demands of this
application are relatively straight forward because of the
high concentration of fluorescent agents being used, but the
application to lower concentration probes will seriously test
the lower limits of systems. A good example of this is in
ALA-PpIX imaging, where concentrations can be present in
tissue at the 1.0–0.01 µM level in vivo. The numbers expected
are important, because current imaging-based systems can
fail to detect this, despite this being a needed goal for the
surgical indication of neurosurgery.46 As a result, direct probe
measurements on the tissue have been developed to detect the
lower levels, simply as a way to gain more optical sensitivity to
the tissue concentration. Increased detection sensitivity or the
ability to discriminate the specific signal from the background
is likely required for growth of the field into specific molecular
reporters. The need to push detection sensitivity to the lowest
levels is also intertwined with the issue of background signal
levels being one of the main limiting performance functions.30
The nature of the background signal is often a compelling
feature which can dominate the technical choice of system.
A key part of most fluorescence guidance systems, which is
different than reflectance imaging systems, is that the effective
background dominates the performance and can limit the
lower sensitivity of the system.30 The factors affecting this
background are several, but the most important are excitation
or ambient light leakage into the fluorescence detector and
getting mixed up with true fluorescence signal.80 Thus,
methods to limit leakage of this contribution to background
from getting into the detector or to remove it from the
processed signal are needed, as illustrated in Fig. 3(a). There
are three primary methods for optimization of the signal
to background ratio. The most important is optimization of
the lens, filter, and camera design, which limits the original
signal from being detected. The second method commonly
employed is temporal gating of the signal [Fig. 3(b)], to
remove ambient light and gate to the excitation pulse.81
The third method employed is some kind of wavelength
filtering or fitting in the detected signal [Fig. 3(c)], which can
remove the broad background which evaded the previous two
methods, and contaminated the detected signal anyway.82–86
The combination of all three approaches to narrowing the
bandwidth in time, spectrum, and space can minimize the
background signal. There are several optional technological
approaches to each of these three, but their implementation
is essential to gaining maximum background removal. One
of the more problematic issues in wavelength filtering has
always been use of suitably effective wavelength filters, as
illustrated in Fig. 3(c). These must be custom produced for
the application when rejection of more than a few orders of
magnitude optical density (OD) is required. Essentially all
fluorescence systems today use custom filters, and sometimes
multiple layers of dielectric and then absorbance filters are
used to further reduce unwanted signals, and the optical design
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F. 3. The main hardware methods to increase signal specificity before camera capture are shown with (i) geometry and filter optimization, (ii) wavelength or
bandwidth restrictions, or (iii) temporal signal processing with mechanical or electronic shuttering. The temporal gating approaches are illustrated in (b) as single
shot pulsed, modulated relative to continuous sampling. Filtering and wavelength processing are illustrated in (c) with typical, custom and specially designed
bandpass filters for detection, and (d) spectral fitting which might be implemented to remove background. The use of HDR principles (e) can allow superior
detection by better background subtraction without loss of pertinent dynamic range. Finally, image texture analysis (f) might be used for improved diagnostic
performance based upon the morphology of the contrast.
to maximize a parallel path of light through the dielectric filter
is essential for proper filtering efficiency. Without these careful
designs, it has been all too common for fluorescence systems
to fundamentally underperform in the area of excitation light
contamination into the detected fluorescence signal.
In the last few years, an important extra layer of background
removal which has been added to some systems is the idea of
spectral fitting of the detected signal, even if strong optical
filtering is done at the input to the detector. This is often
required, because optical filters are known to be imperfect in
all cases, with typical values being about 3 ODs of rejection
for out of band wavelengths, and the best filters being 5 ODs
of rejection. Since the background contamination has different
wavelength dependence, spectral detection and fitting can be
Medical Physics, Vol. 43, No. 6, June 2016
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used to remove it. This requires spectrometer detection or
multispectral imaging capability, which is becoming more
achievable with high speed filter wheels or with liquid crystal
tunable filters. As shown in Fig. 3(d) at right, when the
background is a large fraction of the signal, the process of
spectral fitting can lower the detection threshold by over an
order of magnitude. This design has only been implemented in
preclinical or research grade systems to date, but emergence
of this in clinical systems is likely just a matter of a few years.
However since the spectral fitting is specific to the molecule
and the type of background, this development is a layer of
specialization which needs to be adapted to the needs of the
molecule used to image, but also must be developed in a
manner which is time efficient.
One of the least discussed but critically important parts of
a fluorescence imaging system is the digitized dynamic range
and performance of the camera and lens system used. This
issue is well appreciated in medical imaging, such as in CT
scanners which produce 12-bit images but are displayed on
standard 8-bit monitors, with the appropriate window/level
adjustment to the useful dynamic range.87 Typical optical
CMOS cameras operate on 8-bit output, and color cameras
have three channels of 8-bit color output. Yet fluorescence
signals can easily vary by many orders of magnitude, making
the 255 gray scale values of an 8-bit digitization to have little
value. This can be addressed by moving the field of view in
or out, which varies the irradiance of the excitation source
by the square of the distance to the tissue. This approach,
while practical, can easily limit quantitative interpretation of
the observed intensity, corresponding to the concentration of
fluorophore. A better way to deal with this situation is the
utilization of high dynamic range (HDR) imaging approaches,
with calibrated display of a windowed region [see Fig. 3(e)].
HDR imaging is now widely implemented in commercial
camera systems and provides a logical alternative to the high
overhead needed for high analog to digital conversion bit
depth for single images. The logistic advantage of HDR is
that two exposures are taken of the same imaging field, at low
and high excitation intensities or integration time. Thus the
images can be combined with some calibration to ensure that a
much wider dynamic range is achieved (>16 bit images) than
traditional 8-bit images. In this paradigm, there is no need for
the dramatically higher electronic overhead of 16-bit readout,
but rather is can be simply reading out two 8-bit images. This
approach to high dynamic range imaging is ideally suited for
fast imaging which requires higher contrast capability.
The related issue to increased dynamic range imaging
is how to display the full dynamic range such that it can
be usefully interpreted by the surgical team. While window
and level methods are ubiquitous in radiology, they have
little value in video rate imaging because of the logistical
limitation of changing the values on the fly. But automated
window-level methods combined with automated histogram
normalization can be implanted if done carefully to the
application. Alternatively, logarithmic transformation can
help to adjust the dynamic range to the viewable depth of
the display, avoiding much need for intensive mathematical
processing.87
Methods to view the display of fluorescence in a manner
which is intuitive and logically differentiated from the surgical
field are also growing in importance. There is certainly no
consensus on colors nor methods for display, yet the need
to match the field of view of white light imaging with
computed or segmented emission is critically important. A
recent study by Elliott et al.88 demonstrates how analysis of
the observed color ranges in a view can be used to predict
the maximum color contrast or range available for the added
information of molecular fluorescence. This type of feature
display improvement in either the surgical view or the surgical
monitor will improve the ability to detect and discriminate the
imaged signals, and this becomes even more important when
the dynamic ranges of intensity exceed the viewable dynamic
range of current display monitors. This is an area of major
need, yet little development.
Finally, while much of the molecular imaging world
has focused on raw uptake values, a major shift in
imaging is toward texture analysis of image data, where
the structural features of the tissue are used with machine
learning algorithms, to identify more suspicious areas. It
is quite feasible that the texture analysis of fluorescence
images will provide this type of information as well, since
vascular patterns and nodular cancer regions have specific
morphologies that could be learned by an imaging system.
This type of classification is largely undeveloped in vivo at
a surgical decision tool. But it is well known that structural
patterns of vascular density and size exist in cancer, and
that structural patterns of stroma and epithelial growth exist,
as well. It should be expected that these type of structural
features will appear in the fluorescence image data as well, as
affected by the spatial distribution mechanisms and the tissue
features that provide or inhibit transport. The heterogeneity of
these features is high, and so validation of these biomarkers
would require substantial development and testing. Similar
algorithmic classification looks promising in the related fields
of radiological image analysis89–91 and pathology image
analysis92–95 of cancer.
The systems being advanced into human surgery are largely
macroscopic imaging tools, with fields of view on the order
of centimeters across. While research focus in microscopy
is widespread in academic medicine, there are very few
commercial products being advanced to guide surgery. This is
largely because surgeons tend to be working on the removal
of macroscopic volumes of tissue, and so they require tools
which inform decisions on this size similar scale. Similarly,
tomographic technologies have been advanced in a range of
academic research trials, yet few systems have ever even
entered a surgical trial, because of the steep resolution loss
after just a millimeter of tissue, from optical scattering.96–98
While surgical systems based upon photoacoustic tomography
could likely advance this field productively, because of the
fields of view and sensitivity range, these tools retrieve
their contrast based upon absorption of molecules which
typically must be present in the millimolar concentration
range. Since metabolic and immunologic probes largely exist
in tissue at the micromolar to nanomolar concentration ranges,
photoacoustic tomography imaging may result in limited
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value. Still, research into these devices continues, and it
may be that innovations in the contrast agents make these
more attractive for commercial advancement into clinical
trials. The devices which are now commercially available
for fluorescence molecular imaging are largely based upon
traditional methods of broad field optical excitation using
LEDs or laser illumination, coupled with optical filtering of
the remitted light, focused onto a lower cost imaging sensor.
These workhorse systems have advanced significantly in the
past decade, to the point where there are easily now a dozen
companies competing with FDA approved systems for this
emerging clinical surgery market.
3. MOLECULAR PROBES—GOING BEYOND
VASCULAR PERFUSION AND ASSESSING
MOLECULAR SPECIFICITY
The earliest Food and Drug Administration (FDA) approval
for fluorescence guided imaging happened in 1959, when IC-
green was approved for ophthalmology, to visualize vessels in
the retina.99–101 Later in 1991, it was approved for additional
indications in cardiac output, hepatic function, and liver blood
flow, and this application continues today as a mainstream
of the field, with major advances in the technology used for
imaging, to image faster and at higher resolution. Fluorescein
was approved for ophthalmology use in 1976102,103 and
continues as a staple tool within the field. While these flow
and perfusion probes are the cause of the recent explosion in
systems and use of fluorescence guided surgery, they are also
inherently limiting the potential value to vascular/perfusion
imaging. These agents are not well suited to site specific
binding to proteins, and while they can be packaged into
nanoparticles,104–106 their use a molecular-specific imaging
tools is limited by low emission yield and biochemical
instability issues. As a result, many fluorescence technology
companies have put forth more stable near-infrared dyes
which can be linked to specific proteins. The first to enter a
range of clinical trials has been IRDye® 800CW, which has
been linked to Erbitux, Herceptin, and deoxyglucose to name
a few targeted approaches. Others have made customized
fluorophores which inherently bind to targets, as a novel
single tracer.
A systematic review of the types of targets available and
their relative concentrations illustrates that, as shown in Fig. 4,
physiological molecules can be classified into four broad
categories, including (i) structural features, (ii) metabolic
systems, (iii) immunologic systems, and (iv) genetic
material.107 These features each have many molecular targets
within them, and for the majority of the imaging systems,
structural features have been targeted, simply because they
exist in abundance, with typical concentrations in the
millimolar range. While genetic material might be the
ideally specific goal for targeted imaging, but it exists in
such low concentrations, near picomolar, that it cannot be
imaged with most detection methods. The vast majority of
molecular imaging approaches in oncology have targeted
metabolic features or immunologic features of tumors,108–113
with these typically existing in the range of micromolar
F. 4. The possible range of molecules which could be used for increased
tumor specificity are in the categories of (i) structural, (ii) metabolic, (iii) im-
munologic, or (iv) genetic features of the tissue. Generally the most potential
for high specificity is to the right in this illustration, but the concentrations
available for sensing also decrease dramatically in these categories, and so
the availability of the signal decreases.
quantities, whereas immunologic molecules exist in the range
of nanomolar concentrations. As such, imaging the lower
concentrations likely has more specificity, but also becomes
a much harder signal to capture. For example, mRNA based
sensor probes have been studied for a long time, yet have been
challenging to utilize in vivo at sufficiently low concentrations,
and so would have toxicological effects if used at sufficiently
high concentrations to do useful detection.11,114,115 Still recent
work has shown solid potential for imaging based upon
genetic material in vitro,116 and this may eventually work
well for larger tissue sensing in vivo if able to be achieved
with modest toxicity. However, the most important feature to
recognize from Fig. 4 is that if fluorescence imaging is likely
to succeed with robust signals, the metabolic information
will likely have to be detected with probes in the millimolar
concentration range, which is very achievable for most agents
and imaging systems. However, immunologic sensing will
require detection of signals as low as the nanomolar range,
pushing signal detection to the limits of what is achievable
today with the very best fluorescence imaging systems. Most
commercial systems today could not reach robust nanomolar
sensitivity of their target fluorescent molecule, so only those
which have designed their system to the most stringent
specifications will likely complete in this latter space. This
observation is critically important when choosing a system to
match a targeting agent for clinical trial use.
At present, there is an enormous amount of development
going on in the metabolic and immunologic imaging
realms,117–121 and clinical trials have started on cell surface
receptor based imaging with antibodies and antibody
fragments.20,122–124 Figure 5(a) illustrates the range of protein
components of antibodies which have been explored for
specific binding to cell receptors, ranging from the smallest
binding domain, Affibody® molecules, through binding
domain components of heavy chain and light chain (VH and
VL), fractions, single chain fragments (scFv), to minibodies,
fragments of antibodies (Fab), and full immunoglobulin
proteins (Ig). Generally as the protein size increases, it retains
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F. 5. The range of immunological probes which could be utilized for cell surface receptors are shown (a), with the trade-off that comes with variation in
size, being affinity for metabolic clearance time (Refs. 127 and 133). In (b) the problem of binding versus nonbinding probes is illustrated, in that even a
specifically binding probe has significant signal simply from the wash in and wash out kinetics of perfusion. A nonspecific probe could be utilized to provide
a reference, with the difference between the two being the bound fraction of specific probe (yellow arrows) (Ref. 132). In (c)–(e), an example tumor image is
shown where EGFR-binding affibody labeled with IRDye 800CW (called ABY-029) is shown localizing (d) and a nonspecific affibody control (c). These were
imaged simultaneously after a simultaneous injection, and the fitted difference signal between the two images shows the smaller EGFR + bound region (e).
the full affinity of the binding domain and has the highest
potential for specificity; however, these larger proteins also
can have longer plasma retention times.125–127 The increase
in plasma lifetime leads to more nonspecific signals in vivo
because there is a continuous feed of new dye to the tumor
interstitium. Higher specificity of bound dye usually occurs
in the time sequence when the plasma clearance is dominated
by clearance, as illustrated in Fig. 5(b).
One of the major problems in molecular imaging is the
issue that perfusion supply and clearance of probes tend to
dominante the influence of the probe concentration.128–130
A recent study by Tichauer et al. explored the extent of
this confounder in lymph node imaging with Cetuximab
labeled with IRDye® 800CW. Another example summarized
in Fig. 5(b) shows the time-dependent fluorescent signal
measured in a mouse glioma subcutaneous xenograft after
injection of ABY029 and negative control Affibody molecules
labeled with IRDye680RD. The shape differences between
these two curves are attributed to specific binding activity
in the tumor,131 but spatial variation in the intensity of
the signal can obscure these differences and lead to high
background enhancement [Fig 5(c), top]. In this case, the data
were fit along with image-derived arterial input functions
using a graphical approach to obtain available receptor
concentration map [Fig. 5(c), bottom]. A key conclusion
from these studies is that specific dyes by themselves can
be affected by perfusion and transport processes to the point
where they do not accurately report on specific binding by
itself. Some secondary method to reduce the nonspecific
signal is needed, which could be a physiochemical effect such
as activation of the fluorescence by enzymes, or change in
lifetime or fluorescence intensity by factors such as pH or
membrane breakage effects. The use of combination cocktails
of fluorescent reporters is one proposed methodology to get
a better measure of binding.130,132 No matter which method
is used, it is essential to appreciate that the single molecule
reporters do not always report on specific binding, and so
their use must be interpreted carefully so that the information
is not misinterpreted.
Further probe or probe combination use is emerging in the
clinic, albeit slower than the introduction of new hardware
imaging systems. This issue is primarily one of economics,
which will be discussed in Sec. 4. The methods to enhance
signal from the temporal dynamics of the contrast agent is
a complex one though, and one in which there has been
considerable preclinical study. A summary of methods has
recently been published recently,130 and a brief illustration of
the compartmental flow kinetics is illustrated in Fig. 6(a). In
Fig. 6(b), there is a tabulated list of ways to maximize the
contrast of the tracer, based upon the particular background
that needs to be minimized.
4. FUTURE GROWTH AND MEDICAL ADOPTION
FOR SUCCESS OF MOLECULAR-GUIDED
SURGERY
The metrics for success of any new surgical practice should
ideally be improved patient outcomes or reduced costs for the
same outcome, and in the current climate of cost management,
this latter issue will likely be a key metric of success going
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F. 6. The compartment flow of intravenous tracers are illustrated in (a) along with example kinetics curves, illustrating how the different compartments
of plasma, interstitium, and cell parenchyma contribute to the overall signals in the target and background tissues, as a function of time. In (b), methods for
maximizing the signal relative to background are tabulated, to maximize signal specificity, mostly based around which background signal needs to be minimized.
forward. However, there are secondary factors that are less
financially tangible, which could easily have just as much
influence on the adoption, such as device market position,
patient preference, medical center competition, and litigation
activity.134 The current climate for adoption is being driven
predominantly by the device companies, making systems
available through the 510 K clearance route at the FDA, to be
used for ICG imaging in vivo. The use for other molecular dyes
could come as a later indication approval, for these existing
devices. However, this pathway is the crux of the technology
problem which could occur, and in that devices designed
for ICG, imaging may not perform well for other molecular
probes which have shifted wavelengths or present in tissue
at significantly lower concentrations, and most importantly
higher background tissue levels. The advancements discussed
in Sec. 2 are needed in order to detect the probes discussed in
Sec. 3.
Thus, metrics for adoption and guidelines for industry
need to be made available from professional societies which
are in the space of quantifying interventional procedures.
Several stages of development should precede wider clinical
trials, including (i) calibration approach, (ii) performance
verification, (iii) tissue simulating phantom value, and
(iv) professional society scrutiny. The role of quantification
is still not obviously needed yet, and so is not well defined
in most procedures, and the role that medical physicists
will have in this field is still emerging. Currently device
companies and biomedical engineering research are driving
much of the activity, but as clinical adoption grows, the
shift from company driven practice guidelines to medical
community driven guidelines should occur, and the value in
the stages of system calibration, verification, and quantitative
interpretation will become more apparent. Diagnostic imaging
QA of these devices will likely need to be established, as will
user guidelines, based upon experiences in initial adopting
academic centers. Medical physicists involved in surgical
guidance or fluorescence imaging development will need
to be involved in this pathway toward professional society
consensus.
5. ECONOMICS—DEVELOPMENT MODELS
THAT SPAN THE VALLEY OF DEATH
One of the reasons that new molecular probes are not
emerging quickly is because of the lack of an immediate
economic model in molecular-guided surgery.23 Much of the
focus in molecular probe imaging with nuclear medicine
has been to pair the development of targeted agents to
medical oncology biologic agents, with the thematic goal of
personalized medicine, customized to the disease phenotype.
This goal still has major cost limitations in the diagnostic
probe development which can only be mitigated if the
therapeutic works well in this subpopulation of identified
patients.22 The other major paradigm utilized in the nuclear
medicine world is that of microdose studies, where imaging is
done at subpharmacodynamic dose levels (FDA specifies this
as <30 nM for synthetic drugs such as proteins, or <100 µg
for most imaging agents).135 Both the paired diagnostic-
therapeutic model and the microdose model need to be taken
advantage of in fluorescence molecular-guided surgery.
The concept of optical targeted agents is a similar one, but
the agent is both a diagnostic and a component of the therapy,
because it guides the surgery. This new paradigm is not
approved in the vast majority of settings today, inhibiting
development because of the classic “chicken and egg?”
problem. The question is how does one finance a new contrast
agent to guide surgery when this paradigm does not exist,
and the reimbursement codes and structure for implementing
them do not exist. This means that all new agents and imaging
systems must pass through a premarket approval (PMA)
pathway at the FDA with no existing predicate approach,
and will need to be done for the combination product of the
device and the contrast agent. The lack of an economic pull
of an existing market in surgery is the direct reason for a
lack of development in this field (see Fig. 7). However the
value proposition must be large enough for a company to
invest in, and given the historical modest economic value of
a contrast agent, it means that most major companies would
view this as a moderately poor investment, unless the value of
Medical Physics, Vol. 43, No. 6, June 2016
3152 Pogue et al.: Molecular-guided surgical oncology 3152
F. 7. The classic drug discovery approach to new target therapy is shown in (a) with the economic input of the NIH being almost negligible and restricted to
the early embryonic phase of discovery going up to limited animal testing. In the paradigm of creation of a new molecular contrast agent, in the absence of an
economic pull, NIH funding must have a larger role in creation of a pipeline of testing and evaluation at several levels, going all the way up to pilot phase 0/1
clinical trials, in order to derisk the investment of industry involvement (Ref. 136).
the contrast was higher. Classic contrast agents are used for
vascular or compartment visualization by a radiologist and
are not by themselves considered definitive. This is despite
the large amount of data supporting that fact that challenging
cancers such as glioma or pancreas have the best outcomes
from complete surgical removal, based upon contrast CT or
contrast MRI exam. Still, use of contrast agents during surgery
has the potential to help decisions in the process to visualize
flow, tissue perfusion, and molecular expression, if developed
and applied carefully. However, the first step in this process
is developing the pipeline of useful active molecular contrast
agents.
With the current paradigm, where there is no established
molecular-guided surgery approved, the lack of an economic
pull to develop the pipeline is quite stark and largely has
completely inhibited the pipeline. The drivers and costs are
illustrated in Fig. 7(a), with pilot activity always ongoing
in the range of well below 1×106 dollars/prospective agent,
and being completed in individual labs with neither sufficient
resources nor expertise to carry testing beyond the single
animal model stage. However, going beyond testing in a
single animal model is critical in this particular application,
because the predominant fraction of the signal contrast is
from vascular leakage in tumors, and so the choice of animal
model to test has an inordinately high impact on the results
of the study.136 Thus, one of the major benefits of molecular
targeting of receptors (which are present in the 0–100 nM
concentration in vivo) is that only nanomolar levels of the
imaging agent are really required. The realization of the
synergy here in low dose use together with lower trial costs is
critically important.
The alternative development paradigm that uses this
microdose model is illustrated in Fig. 7(b), where for
highly ambitious research programs, it becomes imperative to
advance the compound through an early phase studies with dye
produced under FDA approved good manufacturing practice
(GMP) production. These are ideally tested in a phase 0/1
trial in humans, under pilot funding. A Phase 0 trial as defined
by the FDA is one where a single microdose concentration of
the imaging agent is used, and the study therefore is not about
safety, but rather just efficacy of the imaging and binding to
the receptors. The peripheral benefit of microdose imaging is
that only a single species toxicity testing is required, without
the need for large animal work, because the dose is expected
to be well below any pharmacodynamic or toxicity effect.
But this study can be used to collect data on specificity of
uptake and binding to the molecules of interest if designed
carefully, and further, if the agents are highly fluorescent in
the near-infrared where there is low background, then it is
feasible to image this low concentration in vivo. This process
allows the demonstration of specificity of uptake in humans,
and then merits further investment into full human trials on
efficacy. The maximum commercial benefit would come if
microdose imaging could be utilized routinely, because then
the requirements for drug production and toxicity testing are
permanently reduced, as is seen in the pipeline for nuclear
medicine agents, as compared to therapeutic agents. This
latter design is almost essential in the absence of an economic
pull of an approve procedure, as is the case for oncology
therapeutics.
6. CONCLUSIONS
This review paper outlines key issues in future system
development as related to molecular probe development and
the costs around advancing them. These dominating issues
each have different levels of success, with the hardware
systems significantly outpacing the molecular probes at this
time. FDA approved hardware systems are almost entirely
cleared for use with a single agent, ICG, at this time, which
is used at a high concentration, and its use in vascular
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imaging requires little background suppression. However
future systems to be utilized for molecular-specific probes
will need to have superior background suppression, and
several preclinical systems and pending approval systems have
implemented the hardware improvements of temporal gating,
wavelength bandwidth improvements, and spectral fitting of
the detected signals needed for these new applications. These
types of hardware fixes, combined with corrections for tissue
optics and calibration, will improve the potential for accurate
use at lower concentration and will make it possible to detect
molecular signals without disturbing the workflow by lighting
changes. However the application of existing hardware tools
to future molecular probe imaging may not be successful
without these important modifications to maximize the signal
to background imaged.
The molecular probe development is lagging the devel-
opment of hardware and software tools; however, preclinical
development is ongoing for a number of innovative molecules
and delivery systems. The key issues which need to be solved
are complicated though, including both nonspecific signal
issues, and the financial issues of how to motivate R&D and
carefully test new agents.
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